AbbVie profit beats on better-than-expected Humira, Botox sales
AbbVie Inc beat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand for Botox amid stiff competition. Investors have been keeping a close eye on falling sales of arthritis drug Humira,…
#abbvieinc #humira #botox #cvshealth #abbvie #skyrizi #rinvoq #immunogen #cereveltherapeutics #revancetherapeutics